The U.S. Department of Defense signed a contract with a U.S. company that will boost capacity of nitrile glove production in the U.S. by 2.31 billion gloves per year by May 2023.
America’s dependence on foreign manufacturers for the supply of personal protective equipment (PPE) became all too painfully obvious during the first months to the COVID-19 pandemic. And the role of infection preventionists in the monitoring of the supply and proper use of PPE also became evident. As stockpiles of PPE became dangerously depleted, U.S. businesses both old and new shifted into entrepreneurial mode to address the problem.
A recent step in this direction was taken last week with an announcement by the U.S. Department of Defense that it signed a $63.6 million deal with a company called US Medical Glove to produce more nitrile gloves in this country. The deal was reached at the urging of the U.S. Department of Health and Human Services (HHS).
“This effort allows US Medical Glove to increase production capacity of nitrile glove production by 2.31 billion gloves per year by May 2023,” US Medical Glove said in a press release. “The Pentagon contract ensures the resources necessary to guarantee quality, safety, technology improvement, customer service in the United States for medical-grade nitrile gloves.”
Also, at a time when the U.S. economy struggles to shake off the aftershocks of the COVID-19 pandemic in which millions of people lost their jobs, the deal will create jobs in this country.
“As many as 3000 direct jobs and 10,000 indirect jobs will be created as US Medical Glove expands to as many as of 6 regional hubs, increasing availability, reducing costs to end users across America,” the company press release states. “Staffing will be driven by a Veterans First program, to offer not just jobs—but livelihoods to our nation’s transitioning military personnel.”
Nitrile gloves can be used in place of latex gloves, according to the to the Centers for Disease Control and Prevention. And according to the Occupational Safety and Health Administration (OSHA) guide to PPE, latex gloves provide flexibility and comfort while nitrile gloves are more durable and better able to protect the wearer from chemicals and punctures.
OSHA states that latex gloves “are comfortable to wear, which makes them a popular general-purpose glove. They feature outstanding tensile strength, elasticity and temperature resistance. In addition to resisting abrasions caused by grinding and polishing, these gloves protect employees’ hands from most water solutions of acids, alkalis, salts and ketones.” However, that agency adds that “latex gloves have caused allergic reactions in some individuals and may not be appropriate for all employees.”
As for nitrile gloves, OSHA says that nitrile gloves “are made of a copolymer and provide protection from chlorinated solvents such as trichloroethylene and per- chloroethylene. Although intended for jobs requiring dexterity and sensitivity, nitrile gloves stand up to heavy use even after prolonged exposure to substances that cause other gloves to deteriorate. They offer protection when working with oils, greases, acids, caustics and alcohols but are generally not recommended for use with strong oxidizing agents, aromatic solvents, ketones and acetates.”
The deal also ensures that the machines to manufacture the nitrile gloves will be built in the U.S. and represents a “decoupling from China as the company brings the business of making high-performance industrial manufacturing equipment back to the United States,” US Medical Glove said in its press release. The company plans to buy about 1 billion pounds U.S. steel, and 535 miles of copper wire made in the U.S., among many other American made components that will be used in the manufacturing process.
Dylan Ratigan, a managing partner at U.S. Medical Glove, said in the press release that “we are honored to be called upon by our government to lead the solution to this problem. Industry and government leaders across the country have unified with us to ensure we exceed expectations on behalf of DoD and HHS for our country.”
Four Years After COVID-19: What Has the Infection Prevention Community Learned?
March 15th 2024Four years ago today, March 15, 2020, the COVID-19 lockdown began, and since then, the world has undergone significant changes. It has been a terrifying experience for everyone, especially for the infection prevention community, both within and outside of the health care sector. However, a crucial question remains unanswered: What has the infection prevention community learned from this pandemic, and where does it go from here?
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.